Relationship between 4-Hydroxynonenal (4-HNE) as Systemic Biomarker of Lipid Peroxidation and Metabolomic Profiling of Patients with Prostate Cancer.
4-hydroynonenal (4-HNE)
GS-MS
LC-MS
cancer
lipid peroxidation
metabolomics
prostate carcinoma
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
10 01 2023
10 01 2023
Historique:
received:
30
11
2022
revised:
29
12
2022
accepted:
04
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
An oxidative degradation product of the polyunsaturated fatty acids, 4-hydroxynonenal (4-HNE), is of particular interest in cancer research due to its concentration-dependent pleiotropic activities affecting cellular antioxidants, metabolism, and growth control. Although an increase in oxidative stress and lipid peroxidation was already associated with prostate cancer progression a few decades ago, the knowledge of the involvement of 4-HNE in prostate cancer tumorigenesis is limited. This study investigated the appearance of 4-HNE-protein adducts in prostate cancer tissue by immunohistochemistry using a genuine 4-HNE monoclonal antibody. Plasma samples of the same patients and samples of the healthy controls were also analyzed for the presence of 4-HNE-protein adducts, followed by metabolic profiling using LC-ESI-QTOF-MS and GC-EI-Q-MS. Finally, the analysis of the metabolic pathways affected by 4-HNE was performed. The obtained results revealed the absence of 4-HNE-protein adducts in prostate carcinoma tissue but increased 4-HNE-protein levels in the plasma of these patients. Metabolomics revealed a positive association of different long-chain and medium-chain fatty acids with the presence of prostate cancer. Furthermore, while linoleic acid positively correlated with the levels of 4-HNE-protein adducts in the blood of healthy men, no correlation was obtained for cancer patients indicating altered lipid metabolism in this case. The metabolic pathway of unsaturated fatty acids biosynthesis emerged as significantly affected by 4-HNE. Overall, this is the first study linking 4-HNE adduction to plasma proteins with specific alterations in the plasma metabolome of prostate cancer patients. This study revealed that increased 4-HNE plasma protein adducts could modulate the unsaturated fatty acids biosynthesis pathway. It is yet to be determined if this is a direct result of 4-HNE or whether they are produced by the same underlying mechanisms. Further mechanistic studies are needed to grasp the biological significance of the observed changes in prostate cancer tumorigenesis.
Identifiants
pubmed: 36671530
pii: biom13010145
doi: 10.3390/biom13010145
pmc: PMC9855859
pii:
doi:
Substances chimiques
4-hydroxy-2-nonenal
K1CVM13F96
Aldehydes
0
Proteins
0
Biomarkers
0
Fatty Acids, Unsaturated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : MINGO, Croatia
ID : CRO_A-00033
Références
Anal Chem. 2014 Apr 1;86(7):3568-74
pubmed: 24635831
Cancer Causes Control. 2014 Mar;25(3):329-38
pubmed: 24384808
PLoS One. 2016 Aug 26;11(8):e0162049
pubmed: 27564706
Arch Physiol Biochem. 2018 Jul;124(3):275-285
pubmed: 29105496
Mol Cancer Res. 2021 Oct;19(10):1727-1738
pubmed: 34131069
Free Radic Biol Med. 2015 Apr;81:128-44
pubmed: 25619142
J Natl Cancer Inst. 2011 Jun 8;103(11):885-92
pubmed: 21498780
Lancet Oncol. 2020 Feb;21(2):222-232
pubmed: 31926806
Cancer Causes Control. 2007 Dec;18(10):1107-21
pubmed: 17726648
EMBO Mol Med. 2016 Oct 4;8(10):1134-1142
pubmed: 27601137
Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2274-9
pubmed: 17119057
Carcinogenesis. 2001 Nov;22(11):1765-73
pubmed: 11698337
J Cell Biochem. 2004 Aug 15;92(6):1246-56
pubmed: 15258907
Diabetes Metab Res Rev. 2015 May;31(4):336-43
pubmed: 25066306
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Free Radic Biol Med. 2011 Oct 15;51(8):1610-8
pubmed: 21816220
Clin Exp Immunol. 2012 Nov;170(2):178-85
pubmed: 23039888
Cancer Epidemiol Biomarkers Prev. 2019 Jan;28(1):189-197
pubmed: 30262599
Free Radic Biol Med. 2017 Oct;111:110-126
pubmed: 27993730
Neoplasia. 2003 Mar-Apr;5(2):135-45
pubmed: 12659686
Biomolecules. 2021 Sep 15;11(9):
pubmed: 34572578
Cells. 2019 Mar 29;8(4):
pubmed: 30934946
Free Radic Biol Med. 2020 Sep;157:128-153
pubmed: 31756524
Endocr Relat Cancer. 2017 Nov;24(11):R403-R420
pubmed: 28924064
Neoplasia. 2009 Jul;11(7):692-9
pubmed: 19568414
Ther Drug Monit. 2005 Dec;27(6):747-51
pubmed: 16404815
Free Radic Res. 2006 Jun;40(6):543-52
pubmed: 16753831
Analyst. 2015 Nov 21;140(22):7810-7
pubmed: 26462549
Biomolecules. 2022 Oct 15;12(10):
pubmed: 36291697
Eur Urol Oncol. 2021 Feb;4(1):56-65
pubmed: 31378665
J Biol Chem. 1964 Jul;239:2194-203
pubmed: 14209948
Urol Clin North Am. 2011 Aug;38(3):243-59
pubmed: 21798387
Prostate. 2021 Aug;81(11):713-720
pubmed: 34097313
J Steroid Biochem Mol Biol. 2000 Dec 1;75(1):1-10
pubmed: 11179903
Cell Mol Life Sci. 2022 Apr 16;79(5):243
pubmed: 35429253
PLoS One. 2010 Aug 11;5(8):e12107
pubmed: 20711410
Front Oncol. 2021 Oct 15;11:730638
pubmed: 34722271
Neurochem Int. 2021 Oct;149:105118
pubmed: 34197897
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Redox Biol. 2013 Feb 08;1:226-33
pubmed: 24024156
Cancer Res. 2008 Jun 1;68(11):4447-54
pubmed: 18519708
Oncotarget. 2016 Oct 11;7(41):67111-67128
pubmed: 27564096
Int J Cancer. 2020 Jan 1;146(1):44-57
pubmed: 30807653
J Proteome Res. 2009 Oct;8(10):4844-50
pubmed: 19678709
Free Radic Res. 2010 May;44(5):497-504
pubmed: 20166882
Free Radic Biol Med. 2017 Jan;102:67-76
pubmed: 27838437
Antioxidants (Basel). 2020 Dec 01;9(12):
pubmed: 33271806
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2807-13
pubmed: 19887582
Biofactors. 2005;24(1-4):89-96
pubmed: 16403967
Biofactors. 2005;24(1-4):33-40
pubmed: 16403961
Redox Biol. 2017 Aug;12:483-490
pubmed: 28334683
Chem Biol. 2011 Jul 29;18(7):846-56
pubmed: 21802006
Cancer Res. 2013 Dec 1;73(23):7009-21
pubmed: 24121491
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W606-12
pubmed: 17584797
Angiogenesis. 2003;6(1):15-24
pubmed: 14517400
Biofactors. 2005;24(1-4):141-8
pubmed: 16403974
Cancer Epidemiol Biomarkers Prev. 2013 Apr;22(4):697-707
pubmed: 23549401
J Exp Med. 2005 Apr 18;201(8):1257-68
pubmed: 15824085
Cancer Res. 2008 Aug 1;68(15):6407-15
pubmed: 18676866
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Oncotarget. 2017 Jun 28;8(40):67506-67518
pubmed: 28978049
Am J Epidemiol. 2012 Aug 1;176(3):240-52
pubmed: 22781428
Redox Biol. 2017 Apr;11:600-605
pubmed: 28110216
Cancer Epidemiol Biomarkers Prev. 2003 Jan;12(1):64-7
pubmed: 12540506
PLoS One. 2010 May 28;5(5):e10883
pubmed: 20526369
Anal Chem. 2013 Nov 19;85(22):10941-8
pubmed: 24144172
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Am J Pathol. 2006 Dec;169(6):2181-98
pubmed: 17148680
Am J Clin Nutr. 2014 Mar;99(3):551-8
pubmed: 24368438
FASEB J. 2013 Sep;27(9):3805-17
pubmed: 23752203
PLoS One. 2012;7(7):e40459
pubmed: 22792336
Asian J Androl. 2022 Sep-Oct;24(5):540-548
pubmed: 35142655
Int J Oncol. 2008 Feb;32(2):357-65
pubmed: 18202758
Front Mol Biosci. 2021 Sep 01;8:723858
pubmed: 34540898
Antioxid Redox Signal. 2015 Nov 10;23(14):1144-70
pubmed: 26415143
Int J Cancer. 2019 Dec 15;145(12):3231-3243
pubmed: 30779128
Int Urol Nephrol. 2004;36(1):57-62
pubmed: 15338676
Anticancer Res. 2001 May-Jun;21(3B):1997-2004
pubmed: 11497289
Front Biosci (Landmark Ed). 2022 Apr 1;27(4):119
pubmed: 35468678
Toxicol Lett. 2002 Jun 7;132(1):27-36
pubmed: 12084617
J Pharm Biomed Anal. 2018 May 30;154:138-149
pubmed: 29547800
Nat Protoc. 2022 Aug;17(8):1735-1761
pubmed: 35715522
Redox Biol. 2016 Oct;9:210-219
pubmed: 27567474
Cancer Causes Control. 2011 Jul;22(7):1011-9
pubmed: 21562751
J Pharm Biomed Anal. 2021 Oct 25;205:114288
pubmed: 34371449
Free Radic Res. 1996 Aug;25(2):149-59
pubmed: 8885333
Indian J Clin Biochem. 2005 Jul;20(2):162-5
pubmed: 23105552
Curr Opin Pharmacol. 2012 Dec;12(6):751-9
pubmed: 22824430
Cancer Causes Control. 2019 Feb;30(2):195-206
pubmed: 30421156
BMC Cancer. 2012 Jan 19;12:25
pubmed: 22260413
Cells. 2022 Jan 27;11(3):
pubmed: 35159254
Cancer Causes Control. 2011 Feb;22(2):311-8
pubmed: 21116843
Proteomics Clin Appl. 2019 Jul;13(4):e1800119
pubmed: 30648813
Am J Epidemiol. 2011 Apr 1;173(7):813-21
pubmed: 21389041
Cell Stem Cell. 2018 Feb 1;22(2):206-220.e4
pubmed: 29395055
J Natl Cancer Inst. 2014 Sep 10;106(9):
pubmed: 25210201
Am J Clin Nutr. 2008 Nov;88(5):1353-63
pubmed: 18996872
Biomed Chromatogr. 2012 May;26(5):548-58
pubmed: 21773981
J Cell Physiol. 2018 Sep;233(9):7367-7378
pubmed: 29663374
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Cancer Res. 2002 Apr 15;62(8):2227-31
pubmed: 11956073
Front Cell Dev Biol. 2021 Jan 12;8:603837
pubmed: 33511116
Cells. 2021 Jan 29;10(2):
pubmed: 33572933
BMC Immunol. 2009 Jan 09;10:1
pubmed: 19134173
Front Oncol. 2022 Jan 20;11:778258
pubmed: 35127481
Sci Rep. 2022 May 19;12(1):8397
pubmed: 35590091
Differentiation. 2011 Nov-Dec;82(4-5):244-52
pubmed: 21862201
Biomolecules. 2015 Sep 30;5(4):2247-337
pubmed: 26437435
Clin Exp Metastasis. 2022 Aug;39(4):641-659
pubmed: 35604506
Cancer Causes Control. 2010 Jan;21(1):61-8
pubmed: 19806465
Cancer Metab. 2014 Sep 01;2:18
pubmed: 25228990
Am J Clin Nutr. 2004 Jul;80(1):204-16
pubmed: 15213050
Anal Chem. 2012 Dec 18;84(24):10768-76
pubmed: 23150939
Cancer Lett. 2008 Feb 18;260(1-2):180-6
pubmed: 18083303
BMC Med. 2022 Oct 25;20(1):362
pubmed: 36280842